ArticleBMC neurology2025
Cerebral microbleeds: prevalence and relationship to clinical features in cognitive impairment with lewy body disease.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comorbid Pathologies and Their Impact on Dementia with Lewy Bodies-Current View.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe burden of cerebral microbleeds (CMBs) is greater in patients with dementia with Lewy bodies (DLB) than in those with Parkinson disease dementia (PDD), while few studies have been carried out in a large sample size, or focused on the prodromal stage. Thus, we investigated the clinical prevalence of CMBs and its relationship to clinical features in patients with DLB, PDD, mild cognitive impairment with Lewy bodies (MCI-LB) and Parkinson's disease with MCI (PD-MCI) in this study.
methodsIn this retrospective multicenter cohort study, the study population consisted of 486 patients with DLB, 262 cases with PDD, 74 cases with MCI-LB and 107 cases with PD-MCI from 22 memory clinics between January 2018 and June 2022 in China. Demographic and clinical information were collected by reviewing medical records. CMBs were classified as "present" or "absent" in the Gradient Recalled-Echo or Susceptibility Weighted Imaging.
resultsThe prevalence of CMBs was significantly greater in patients with DLB with 24.69% (95% CI [20.92%, 28.78%]) than patients with PDD with 20.23% (95% CI [5.54%, 25.61%]), patients with MCI-LB with 16.22% (95% CI [8.67%, 26.61%]), and patients with PD-MCI with 12.15% (95% CI [6.63%, 19.88%]). There were sex and age differences in this prevalence. In all patients, the presence of CMBs was significantly and independently associated with the presence of visual hallucination (OR = 1.597, 95% CI [1.014, 2.517], p = 0.044) and fluctuating cognition (OR = 1.707, 95% CI [1.140, 2.556], p = 0.009); and it was associated with the severity of hallucination (B = 0.775, SE = 0.368, p = 0.036) and disinhibition (B = 0.363, SE = 0.148, p = 0.014) reflected by NPI. Moreover, CMBs in DLB were associated with the presence of parkinsonism symptoms (OR = 1.821, 95% CI [1.001, 3.314], p = 0.05), and the scores of UPDRS-III (B = 4.711, SE = 1.939, p = 0.016) and Hoehn-Yahn stage (B = 0.452, SE = 0.165, p = 0.007).
conclusionPatients with DLB had a higher proportion of CMBs than PDD, MCI-LB and PD-MCI. CMBs in all DLB, PDD, MCI-LB and PD-MCI cases were associated with the presence of visual hallucination and fluctuating cognition; in DLB were associated with motor function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.